{"DataElement":{"publicId":"3227313","version":"1","preferredName":"Laboratory Procedure Breast Neoplasm Tumor Marker Evaluation Breast Tumor Marker Unit of Measure","preferredDefinition":"the unit of measure, a named quantity in terms of which other quantities are measured or specified used as a standard measurement, for a procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for biomarkers related to a benign or malignant neoplasm originating in the breast parenchyma.","longName":"3227279v1.0:3227297v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3227279","version":"1","preferredName":"Laboratory Procedure Breast Neoplasm Tumor Marker Evaluation","preferredDefinition":"information related to any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for biomarkers related to a benign or malignant neoplasm originating in the breast parenchyma.","longName":"2543047v1.0:3227277v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3227277","version":"1","preferredName":"Breast Neoplasm Tumor Marker Evaluation","preferredDefinition":"A benign or malignant neoplasm of the breast parenchyma.  It can originate from the ducts, lobules or the breast adipose tissue.  Breast neoplasms are much more common in females than males. -- 2003:A substance sometimes found in an increased amount in the blood, other body fluids, or tissues and which may mean that a certain type of cancer is in the body. Examples of tumor markers include CA 125 (ovarian cancer), CA 15-3 (breast cancer), CEA (ovarian, lung, breast, pancreas, and gastrointestinal tract cancers), and PSA (prostate cancer). Also called biomarker.:Evaluation; the act of placing value on something.","longName":"C2910:C17220:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Neoplasm","conceptCode":"C2910","definition":"A benign or malignant neoplasm of the breast parenchyma. It can originate from the ducts, lobules or the breast adipose tissue. Breast neoplasms are much more common in females than males.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CE4CD0-3011-8CD2-E040-BB89AD4304CE","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CE4CD0-3022-8CD2-E040-BB89AD4304CE","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3227297","version":"1","preferredName":"Breast Tumor Marker Unit of Measure","preferredDefinition":"information related to the unit of measure, a named quantity in terms of which other quantities are measured or specified used as a standard measurement of same kinds, such as pound or kilogram in measuring weight, for a tumor marker for breast cancer.","longName":"3227297v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Ki67 by immunohistochemistry %","valueDescription":"Ki67 by immunohistochemistry %","ValueMeaning":{"publicId":"3227298","version":"1","preferredName":"Ki67 by immunohistochemistry %","longName":"3227298","preferredDefinition":"Ki67 by immunohistochemistry %","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-39B8-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-39D1-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"Thymidine labelling index","valueDescription":"Thymidine labelling ind","ValueMeaning":{"publicId":"3227299","version":"1","preferredName":"Thymidine labelling ind","longName":"3227299","preferredDefinition":"Thymidine labelling ind","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-39DB-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-39F4-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"CISH TOPO II:CEP17 ratio","valueDescription":"Topoisomerase II Chromosome 17 Ratio Chromogenic in situ Hybridization","ValueMeaning":{"publicId":"3227301","version":"1","preferredName":"Topoisomerase II Chromosome 17 Ratio Chromogenic in situ Hybridization","longName":"3227301","preferredDefinition":"Topoisomerase II catalyzes relaxation of supercoiled DNA molecules, catenation, decatenation, knotting, and unknotting of circular DNA.  The topoisomerase II reaction appears to involve crossing-over of two DNA segments.  Human cells contain two topoisomerase II isozymes: alpha and beta from distinct genes.  DNA topoisomerase II alpha is associated with the Pol II holoenzyme and is required for chromatin-dependent co-activation.  Transcription results in superhelical tension; topoisomerase II relaxation activity is essential for productive RNA synthesis on nucleosomal DNA.  (from OMIM 126430 and NCI): The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.: The ratio of two or more signals, typically between two channels.  Of type float. (caMAGE): Chromogenic in situ hybridization is a technique that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase II","conceptCode":"C18434","definition":"Topoisomerase II catalyzes relaxation of supercoiled DNA molecules, catenation, decatenation, knotting, and unknotting of circular DNA.  The topoisomerase II reaction appears to involve crossing-over of two DNA segments.  Human cells contain two topoisomerase II isozymes: alpha and beta from distinct genes.  DNA topoisomerase II alpha is associated with the Pol II holoenzyme and is required for chromatin-dependent co-activation.  Transcription results in superhelical tension; topoisomerase II relaxation activity is essential for productive RNA synthesis on nucleosomal DNA.  (from OMIM 126430 and NCI)","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Human Chromosome 17","conceptCode":"C13212","definition":"The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ratio","conceptCode":"C44256","definition":"Quotient of quantities of the same kind for different components within the same system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chromogenic In Situ Hybridization","conceptCode":"C40960","definition":"A laboratory procedure that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3A04-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3A1D-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"CISH HER2:CEP17 ratio","valueDescription":"HER2/neu Chromosome 17 Ratio Chromogenic in situ Hybridization","ValueMeaning":{"publicId":"3227302","version":"1","preferredName":"HER2/neu Chromosome 17 Ratio Chromogenic in situ Hybridization","longName":"3227302","preferredDefinition":"The ERBB2 Gene at 17q21.1 encodes ERRB2 Receptor Protein Tyrosine Kinase, a 185 kD type I membrane glycoprotein that controls cell growth with features similar to EGFR. Ligand binding increases phosphorylation of tyrosine residues. A potential heterodimer with ERBB3 and ERBB4 receptors, p185ERBB2 is an essential component of the heregulin/neuregulin receptor complex. ERBB2 homodimers do not bind heregulin but ERBB2/ERBB3 heterodimers do. Neuregulins do not interact with ERBB2 alone. The IL6 cytokine induces tyrosine phosphorylation of ERBB2 and ERBB3, but not EGFR. ERBB2 forms an IL6-dependent complex with the IL6R gp130 subunit resulting in MAPK activation. Expressed in fetal kidney and liver, herstatin is a 68 kD secreted product of an alternative ERBB2 transcript that retains intron 8. Herstatin binds p185ERBB2 as an inhibitor by disrupting ERBB2 dimers and reducing p185 tyrosine phosphorylation.  (from SWISS-PROT, OMIM and NCI): The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.: The ratio of two or more signals, typically between two channels.  Of type float. (caMAGE): Chromogenic in situ hybridization is a technique that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ERBB2 Gene","conceptCode":"C17756","definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Human Chromosome 17","conceptCode":"C13212","definition":"The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ratio","conceptCode":"C44256","definition":"Quotient of quantities of the same kind for different components within the same system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chromogenic In Situ Hybridization","conceptCode":"C40960","definition":"A laboratory procedure that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3A31-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3A4A-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"CISH # of copies","valueDescription":"Copy Number Chromogenic in situ Hybridization","ValueMeaning":{"publicId":"3227303","version":"1","preferredName":"Copy Number Chromogenic in situ Hybridization","longName":"3227303","preferredDefinition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.: Chromogenic in situ hybridization is a technique that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copy Number","conceptCode":"C49142","definition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chromogenic In Situ Hybridization","conceptCode":"C40960","definition":"A laboratory procedure that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3A57-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3A70-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"FISH HER2:CEP17 ratio","valueDescription":"HER2/neu Chromosome 17 Ratio Fluorescence in situ Hybridization","ValueMeaning":{"publicId":"3227304","version":"1","preferredName":"HER2/neu Chromosome 17 Ratio Fluorescence in situ Hybridization","longName":"3227304","preferredDefinition":"The ERBB2 Gene at 17q21.1 encodes ERRB2 Receptor Protein Tyrosine Kinase, a 185 kD type I membrane glycoprotein that controls cell growth with features similar to EGFR. Ligand binding increases phosphorylation of tyrosine residues. A potential heterodimer with ERBB3 and ERBB4 receptors, p185ERBB2 is an essential component of the heregulin/neuregulin receptor complex. ERBB2 homodimers do not bind heregulin but ERBB2/ERBB3 heterodimers do. Neuregulins do not interact with ERBB2 alone. The IL6 cytokine induces tyrosine phosphorylation of ERBB2 and ERBB3, but not EGFR. ERBB2 forms an IL6-dependent complex with the IL6R gp130 subunit resulting in MAPK activation. Expressed in fetal kidney and liver, herstatin is a 68 kD secreted product of an alternative ERBB2 transcript that retains intron 8. Herstatin binds p185ERBB2 as an inhibitor by disrupting ERBB2 dimers and reducing p185 tyrosine phosphorylation.  (from SWISS-PROT, OMIM and NCI): The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.: The ratio of two or more signals, typically between two channels.  Of type float. (caMAGE): A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ERBB2 Gene","conceptCode":"C17756","definition":"This gene plays a role in cellular proliferation and is involved in the oncogenic process through amplification and/or overexpression in several cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Human Chromosome 17","conceptCode":"C13212","definition":"The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ratio","conceptCode":"C44256","definition":"Quotient of quantities of the same kind for different components within the same system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorescence In Situ Hybridization","conceptCode":"C17563","definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3A7F-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3A98-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"FISH # of copies","valueDescription":"Copy Number Fluorescence in situ Hybridization","ValueMeaning":{"publicId":"3227305","version":"1","preferredName":"Copy Number Fluorescence in situ Hybridization","longName":"3227305","preferredDefinition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Copy Number","conceptCode":"C49142","definition":"The number of molecules of a particular type on or in a cell or part of a cell. Usually applied to specific genes or to plasmids within a bacterium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fluorescence In Situ Hybridization","conceptCode":"C17563","definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3AA5-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3ABE-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"Immunohistochemistry score","valueDescription":"Score Immunohistochemistry Staining Method","ValueMeaning":{"publicId":"3227306","version":"1","preferredName":"Score Immunohistochemistry Staining Method","longName":"3227306","preferredDefinition":"A number or range of numeric values measuring performance, function, quality, or ability.: Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Score","conceptCode":"C25338","definition":"A number or range of numeric values measuring performance, function, quality, or ability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3ACB-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3AE4-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"Immunohistochemistry % staining","valueDescription":"Percentage Immunohistochemistry Staining Method","ValueMeaning":{"publicId":"3227307","version":"1","preferredName":"Percentage Immunohistochemistry Staining Method","longName":"3227307","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.: Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3AF1-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3B0A-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"H-score","valueDescription":"H-score","ValueMeaning":{"publicId":"3227308","version":"1","preferredName":"H-score","longName":"3227308","preferredDefinition":"A method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3B14-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3B2D-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"Allred score","valueDescription":"Allred score","ValueMeaning":{"publicId":"3227309","version":"1","preferredName":"Allred score","longName":"3227309","preferredDefinition":"A composite of the percentage of cells that stained and the intensity of their staining.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3B37-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3B50-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"% cells staining positive","valueDescription":"Percent of cells staining positive","ValueMeaning":{"publicId":"3227310","version":"1","preferredName":"Percent of cells staining positive","longName":"3227310","preferredDefinition":"Percent of cells staining positive","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3B5A-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3B73-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"fmol/mg","valueDescription":"fentomoles per milligram","ValueMeaning":{"publicId":"3227311","version":"1","preferredName":"fentomoles per milligram","longName":"3227311","preferredDefinition":"fentomoles per milligram","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3B7D-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3B96-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2839905","version":"1","preferredName":"Other","longName":"2839905","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"635B8107-2331-1337-E040-BB89AD432C60","latestVersionIndicator":"Yes","beginDate":"2009-02-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3BA0-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"},{"value":"S-Phase Fraction","valueDescription":"S-Phase Fraction","ValueMeaning":{"publicId":"3227312","version":"1","preferredName":"S-Phase Fraction","longName":"3227312","preferredDefinition":"The percentage of cells in a sample currently undergoing mitosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"S-Phase Fraction","conceptCode":"C18456","definition":"The percentage of cells in a sample currently undergoing mitosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-3BAB-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A0CEDAE8-3BC4-3915-E040-BB89AD434032","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"ONEDATA","dateModified":"2011-04-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233053","version":"1","preferredName":"Unit of Measure","preferredDefinition":"A named quantity in terms of which other quantities are measured or specified used as a standard measurement of same kinds, such as pound or kilogram in measuring weight. (NCI)","longName":"C25709","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unit of Measure","conceptCode":"C25709","definition":"A named quantity in terms of which other quantities are measured or specified, used as a standard measurement of like kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-B9EC-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-06-08","modifiedBy":"ONEDATA","dateModified":"2005-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CEDAE8-39A3-3915-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"CAMPBELB","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811957","version":"1","longName":"Labs","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Units","type":"Preferred Question Text","description":"Units","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0CF1926-C697-62D0-E040-BB89AD4377B6","latestVersionIndicator":"Yes","beginDate":"2011-04-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-13","modifiedBy":"CAMPBELB","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}